A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

This study is a phase I, open-label, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ALPS12 in patients with extensive-stage small cell lung cancer. The study consists of two parts: a dose-escalation part and an expansion part.

Trial Details

NCT ID
NCT07107490
Phase
PHASE1
Sponsor
Chugai Pharmaceutical
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • ALPS12
  • obinutuzumab
Locations (sample)
  • Hong Kong, Hong Kong|22.27832,114.17469
  • Kashiwa, Chiba, Japan|35.86224,139.97732
  • Tōon, Ehime, Japan|33.79427,132.89011
  • Sakai, Osaka, Japan|34.58216,135.46653
  • Niigata, Japan|37.92259,139.04125

Key Eligibility Criteria

  • Aged \>18 years at time of informed consent
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1
  • Histologically documented extensive stage small cell lung cancer
  • Disease recurrence documented after at least one prior systemic therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →